


Dapsone-d8

Cat. No.:	HY-B0688S		
CAS No.:	557794-38-4		
Molecular Formula:	C ₁₂ H ₄ D ₈ N ₂ O ₂ S		
Molecular Weight:	256.35		
Target:	Antibiotic; Parasite; Bacterial; Reactive Oxygen Species		
Pathway:	Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	Dapsone D8 (4,4'-Diaminodiphenyl sulfone D8) is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities ^[1] . Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of <i>M. leprae</i> . Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases ^{[2][3][4][5]} .								
In Vitro	Dapsone (0.06 mM; 30 min) suppresses intra- and extracellular production of superoxide (O ₂ ⁻) and elastase release triggered by N-Formyl-Met-Leu-Phe (HY-P0224) (1 μM) and physiological agonist C5a (100 nM), but not by Phorbol 12-myristate 13-acetate (HY-18739) (100 nM) ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Dapsone (5 mg/kg; i.p.; single dose) shows neuroprotective effects and substantially improves memory acquisition in Scopolamine (HY-N0296)-induced memory impairment in mice ^[6] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Scopolamine-induced memory impairment model in mice^[6]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 0.3, 1, 5, and 10 mg/kg; 1 mg/kg for Scopolamine</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single dose</td> </tr> <tr> <td>Result:</td> <td>Improved memory acquisition.</td> </tr> </table>	Animal Model:	Scopolamine-induced memory impairment model in mice ^[6]	Dosage:	0.1, 0.3, 1, 5, and 10 mg/kg; 1 mg/kg for Scopolamine	Administration:	Intraperitoneal injection; single dose	Result:	Improved memory acquisition.
Animal Model:	Scopolamine-induced memory impairment model in mice ^[6]								
Dosage:	0.1, 0.3, 1, 5, and 10 mg/kg; 1 mg/kg for Scopolamine								
Administration:	Intraperitoneal injection; single dose								
Result:	Improved memory acquisition.								

REFERENCES

- [1]. Wozel G, et al. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014 Mar;306(2):103-24.
- [2]. Noroozi N, et al. Protective Effects of Dapsone on Scopolamine-Induced Memory Impairment in Mice: Involvement of Nitric Oxide Pathway. Dement Geriatr Cogn Dis Extra. 2022 Mar 24;12(1):43-50.
- [3]. Yi Zhu, et al. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol
- [4]. Dapsone. Drug.com

[5]. D Voeller, et al. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). J Infect Dis. 1994 Feb;169(2):456-9.

[6]. Esther Moreno, et al. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions. Pharmaceutics. 2019 Nov 13;11(11):607.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA